Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes

被引：66

作者：

Geusens, B. ^{[1
]}

Lambert, J. ^{[1
]}

De Smedt, S. C. ^{[2
]}

Buyens, K. ^{[2
]}

Sanders, N. N. ^{[2
,3
]}

Van Gele, M. ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Dermatol, B-9000 Ghent, Belgium

[2] Univ Ghent, Lab Gen Biochem & Phys Pharm, B-9000 Ghent, Belgium

[3] Univ Ghent, Lab Gene Therapy, Dept Nutr Genet & Ethol, Fac Vet Med, B-9820 Merelbeke, Belgium

来源：

JOURNAL OF CONTROLLED RELEASE | 2009年 / 133卷 / 03期

关键词：

Ultradeformable liposomes; Delivery vehicle; Skin; Melanocytes; siRNA; DRUG CARRIERS; TRANSDERMAL DELIVERY; TRIAMCINOLONE-ACETONIDE; TRANSFECTION EFFICIENCY; TOPICAL APPLICATION; INTACT SKIN; DNA; VESICLES; EXPRESSION; IMMUNIZATION;

D O I：

10.1016/j.jconrel.2008.10.003

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The aim of this work was to develop a system that can deliver siRNA into cells present in the human epidermis. More specifically, we wanted to block the expression of a specific Myosin Va exon F containing isoform that is physiologically involved in melanosome transport in human melanocytes. Therefore, we prepared and investigated the capacity of ultradeformable cationic liposomes (UCLs) to deliver siRNA in hard-to-transfect human primary melanocytes. UCLs were formulated from different w:w ratios (6:1, 8:1 and 10:1) of the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and the edge activator sodium cholate. Subsequently, UCL/siRNA complexes were prepared and their particle size, surface charge, deformability, cytotoxicity, transfection efficiency and long-term stability were tested. The best results were obtained with UCLs composed of a DOTAP/NaChol ratio of 6:1 (w:w) which are promising for future in vivo experiments. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：214 / 220

页数：7

共 49 条

[1]

Aigner A, 2007, CURR OPIN MOL THER, V9, P345

[2] LIPOSOME-MEDIATED GENE-TRANSFER AND EXPRESSION VIA THE SKIN [J].

ALEXANDER, MY ;

AKHURST, RJ .

HUMAN MOLECULAR GENETICS, 1995, 4 (12) :2279-2285

[3] Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix) [J].

Babiuk, S ;

Baca-Estrada, ME ;

Pontarollo, R ;

Foldvari, M .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (12) :1609-1614

[4]

Barry B.W., 1983, DERMATOLOGICAL FORMU

[5] Novel mechanisms and devices to enable successful transdermal drug delivery [J].

Barry, BW .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (02) :101-114

[6] Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes [J].

Birchall, JC ;

Marichal, C ;

Campbell, L ;

Alwan, A ;

Hadgraft, J ;

Gumbleton, M .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 197 (1-2) :233-238

[7] Skin structure and mode of action of vesicles [J].

Bouwstra, JA ;

Honeywell-Nguyen, PL .

ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 :S41-S55

[8] Transidermal drug delivery of insulin with ultradeformable carriers [J].

Cevc, G .

CLINICAL PHARMACOKINETICS, 2003, 42 (05) :461-474

[9] LIPID VESICLES PENETRATE INTO INTACT SKIN OWING TO THE TRANSDERMAL OSMOTIC GRADIENTS AND HYDRATION FORCE [J].

CEVC, G ;

BLUME, G .

BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1104 (01) :226-232

[10] Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin [J].

Cevc, G ;

Gebauer, D ;

Stieber, J ;

Schätzlein, A ;

Blume, G .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1998, 1368 (02) :201-215

← 1 2 3 4 5 →